Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

contract. In 2009 we will have a continued strong focus on fulfilling this contract as well as a strong focus on preparing for the Phase III studies that we expect to initiate with both IMVAMUNE(R) and PROSTVAC(TM) in 2010."

Strong foundation for future growth and earnings

Despite the financial crisis and an economic slowdown, Bavarian Nordic recorded a positive development in 2008, and has laid a strong foundation for further value creation in 2009 and the years ahead. The expected positive development is based on the following elements:

    - Two vaccines moving into Phase III trials

    - Strong financial position

    - Profitable ongoing development and procurement contracts with a value
      of more than DKK 3.5 billion

    - Expectations to the US government's exercise of the contract option for
      additional development and procurement, worth more than DKK 6 billion

    - Ongoing contracts with countries outside USA

    - Partnership with the NCI, a world leading cancer research organisation

    - Strong patent portfolio

    - Pipeline with promising results

    - Future licensing agreement for PROSTVAC(TM)

    - The world's only manufacturing facility dedicated to the
      commercial-scale production of MVA based vaccines

    Important events after the balance sheet date
    IMVAMUNE(R) - end-of-Phase II meeting held with the FDA

After concluding the Phase II development of IMVAMUNE(R), Bavarian Nordic held an end-of-Phase-II meeting with the US health authorities (FDA) in the beginning of 2009 in order to discuss the Phase III study design. The meeting was a success and there was an open and highly constructive discussion with the FDA. Based on the meeting, Phase III studies are expected to be initiated in 2010.

The outcome of the meeting has no impact on the delivery of vaccines to the Strategic National Stockpile (SNS) under the RFP-
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... DES MOINES, Iowa (PRWEB) July 23, 2014 ... will join the business as vice president of Agricultural ... from Mendel Biotechnology where he served most recently as ... brings extensive biotechnology and business leadership in the seed ... DuPont Pioneer,” said Paul E. Schickler , president ...
(Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 /PRNewswire/ - ... industrial biotechnology company producing sustainable chemicals, today announced that ... in full their option to purchase an additional ... offering price of $12.00 per share, less underwriting ... announced underwritten public offering of 2,800,000 shares of ...
(Date:7/23/2014)... regulated information -- UCB today announced an important advance ... topline results from the latest Phase 3 study ... evaluate the efficacy and safety of brivaracetam ... to placebo, as adjunctive treatment in adult focal ... despite treatment with one or two concomitant antiepileptic ...
(Date:7/23/2014)... , July 23, 2014 ... ), the global specialty biopharmaceutical company, and ArmaGen, ... a worldwide licensing and collaboration agreement for AGT-182, ... potential treatment of both the central nervous system ... syndrome (MPS II). This collaboration strengthens Shire,s rare ...
Breaking Biology Technology:DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5
... Bunge North America, the North American operating arm of Bunge ... which can be attributed to Soren Schroder, Bunge North America ... aware from press reports of Syngenta,s allegations.  From what we ... and disappointed that Syngenta has taken an action which could ...
... 23, 2011 MedNet Solutions, a global life sciences technology ... to announce that MedNet has once again been recognized by ... held companies in the United States.  MedNet is greatly honored ... straight year, since, as noted by Inc . magazine, ...
... FMC Corporation (NYSE: FMC ) announced today ... agreements covering global development and supply of Chr. Hansen ... begin commercialization this year of Chr. Hansen,s Nemix bacillus ... standalone and combination products in the Americas and key ...
Cached Biology Technology:Bunge Responds to Syngenta Suit 2MedNet Solutions Achieves the Inc. 5000 List Five Years in a Row 2FMC Corporation Announces Exclusive Global Development and Supply Agreements for Chr. Hansen Biological Products 2
(Date:7/23/2014)... for providing essential fatty acids and energy to ... has been concern that soybean-based emulsions could compromise ... its composition. Combination lipid emulsions based on triglyceride ... developed to address this concern. , However, researchers ... may be unwarranted, according to a review published ...
(Date:7/22/2014)... consists of both still images and video of ... research. Forty-four still images were chosen from more ... staff, and alumni representing more than 25 different ... than 50 submissions. , Zach Donnell, a graduate ... 2014 organizers, noted that the exhibit highlights the ...
(Date:7/22/2014)... (NASDAQ: AWRE ), a leading supplier of biometrics ... quarter ended June 30, 2014. Revenue for the ... 53% compared to $4.4 million in the same quarter last ... quarter of 2014 was $1.4 million compared to $0.5 million ... and operating income was driven by higher sales of software ...
Breaking Biology News(10 mins):Art of Science 2014 2Aware, Inc. Reports Second Quarter 2014 Financial Results 2Aware, Inc. Reports Second Quarter 2014 Financial Results 3Aware, Inc. Reports Second Quarter 2014 Financial Results 4Aware, Inc. Reports Second Quarter 2014 Financial Results 5Aware, Inc. Reports Second Quarter 2014 Financial Results 6Aware, Inc. Reports Second Quarter 2014 Financial Results 7
... , June 19, 2013  Paris Air Show – ... Systems) , a leading provider of innovative test solutions ... solutions this week at the Paris Air Show ... complex armament systems with longer lifecycles, industry leaders are ...
... University, sophisticated computational models and advances in graphical processing ... genomic data, virus structure and the formation of the ... "We hope that some of what we are ... unable to replicate," says post-doctoral fellow Jason Perlmutter, first ...
... Washington, D.C. June 18, 2013 Joshua Obar, ... UniversityBozeman, has been honored with a 2013 ICAAC Young ... the regulation of immunological memory responses to infection. ... Wesleyan University in 2001 and went on to complete ...
Cached Biology News:Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3Computer modeling technique goes viral at Brandeis 2The American Society for Microbiology honors Joshua Obar 2
Required to perform reference file generation, flatfield calibration and performance verification processes on the GSD-501...
... The 2.0 network client/server version of Freezerworks ... workflow in high-volume labs and facilitates the sharing ... to share sample information. ... PowerPC (100MHz, PPC 601); 13 in monitor with ...
... 500 reactions. Prepare circular DNA templates ... microgram quantities of template DNA from ... DNA directly for cycle sequencing without ... liquid cultures, colonies, plaques, or purified ...
...
Biology Products: